Sex-specific cytokine signatures as predictors of anti-PD1 therapy response in non-small cell lung cancer
Plasma cytokine levels can be useful biomarkers for predicting response to anti-PD1 therapy in NSCLC patients. However, the data presented in this study demonstrate that sex needs to be considered as an important variable in biomarker studies in immuno-oncology due to sex disparities in correlations of cytokines to anti-PD1 treatment response.
Authors
- Mahmoud Abdelsalam (ORCID: https://orcid.org/0000-0002-6879-1107)
- Ammar Sabir Cheema
- Nicholas Finn (ORCID: https://orcid.org/0000-0002-4908-6824)
- Karama Asleh (ORCID: https://orcid.org/0000-0002-2873-7253)
- Rodney J. Ouellette (ORCID: https://orcid.org/0000-0002-2281-2769)
- Cathy Taylor (ORCID: https://orcid.org/0000-0002-7862-6981)
Institutions
- Dalhousie University (CA)
- Université de Moncton (CA)
- Moncton Hospital (CA)
- Atlantic Cancer Research Institute (CA)
- Vitalité Health Network (CA)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1583421
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Canadian Cancer Society